Calidi Biotherapeutics has granted an inducement non-qualified stock option to newly appointed VP Finance, Controller Sandra Gurrola for the purchase of 100,000 shares at an exercise price of $0.15, the closing price on the July 6, 2026 grant date. The option vests over four years, with 25% vesting on the one-year anniversary and the remainder in equal monthly installments through July 6, 2030. The grant was approved by the Compensation Committee and Board of Directors as a material inducement to Ms. Gurrola’s employment under Section 711 of the NYSE American LLC Company Guide.
Calidi Biotherapeutics Inc.Grant of stock option to new VP Finance is a routine inducement, not material to company performance.